BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q3 2025 Earnings Call Transcript
Operator: Good afternoon. I will be your conference operator today.
Bridgebio Pharma Inc. (BBIO)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 15,977,849 | $829,889,477 | -14% | 2.16% |
| 2. | Farallon Capital Thomas Steyer | 8,192,000 | $425,492,480 | +4% | 1.74% |
| 3. | D E Shaw D. E. Shaw | 2,252,762 | $117,008,458 | +9% | 0.07% |
| 4. | 67,624,000 | $94,906,522 | 1.15% | ||
| 5. | Laurion Capital Management Benjamin A. Smith | 1,753,544 | $91,079,076 | -28% | 1.57% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 1,752 | $24,948.48 | 3,294 | 2021-12-29 | Filing | |
| $13.16 | 796 | $10,475.36 | 2,687 | 2021-12-28 | Filing | |
| $12.68 | 1,542 | $19,552.56 | 1,542 | 2021-12-28 | Filing | |
| $12.68 | 1,542 | $19,552.56 | 3,433 | 2021-12-28 | Filing | |
| $13.18 | 1,891 | $24,923.38 | 1,891 | 2021-12-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $74.26 | 2,000 | $148,520.00 | 130,297 | 2025-12-08 | Filing | |
| $73.75 | 7,712 | $568,758.46 | 4,558,447 | 2025-12-05 | Filing | |
| $73.04 | 12,288 | $897,529.04 | 4,566,159 | 2025-12-05 | Filing | |
| $74.80 | 5,700 | $426,357.72 | 4,578,447 | 2025-12-04 | Filing | |
| $74.42 | 12,200 | $907,970.36 | 4,584,147 | 2025-12-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,832,059 | $874,257,145 | 0.01% | |
| 2. | 14,411,203 | $748,517,884 | 0.01% | |
| 3. | 13,260,971 | $688,774,834 | 11.54% | |
| 4. | 8,741,079 | $453,956,601 | 0.21% | |
| 5. | 6,089,611 | $316,294,395 | 69.29% |
News See All
BridgeBio Pharma (BBIO) Soars to All-Time High on Stellar Drug Trial Result
BridgeBio rallied for a third straight day on Monday to hit a new all-time high as investors snapped up shares following the stellar results of its final clinical trial for the study of BBP-418 in patients...
UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) Retains $68 Target on Strong Launch Dynamics
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is among the most promising biotech stocks to buy according to hedge funds.
7 Most Promising Biotech Stocks to Buy According to Hedge Funds
If there’s one sector that is gaining popularity each day, it’s definitely the biotechnology market.
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
BridgeBio Pharma's Encaleret Shows Positive Phase 2 Results, Normalizes Calcium in Post-Surgical Hypoparathyroidism
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the most promising long-term stocks to buy.
11 Best Performing Long Term Stocks According to Analysts
Alli McCartney of UBS noted that the market’s behavior after the recent Fed rate cut was unusual. On the day of the cut, major indices closed lower except for the Russell 2000.
12 Most Promising Long-Term Stocks to Buy
On September 12, Abby Joseph Cohen, Columbia Business School professor and former Goldman Sachs partner & chief US strategist, joined 'Squawk Box' on CNBC to discuss the latest market trends, state of...
13 Best Mid Cap Growth Stocks to Buy According to Hedge Funds
On August 26, Courtney Garcia, Payne Capital Management senior wealth advisor, joined CNBC television for an interview to discuss whether investors should continue buying in the current market scenario...
Hedge Fund Resource Center Billionaire Hedge Funds
